AbCellera today announced that it has entered into an agreement with Alloy Therapeutics to use the ATX-Gx™ humanized mice platform to enable best-in-class in vivo human antibody discovery for its partner programs. Under the terms of the agreement, AbCellera will offer its biotech and pharma partners access to ATX-Gx™, Alloy’s proprietary suite of immunocompetent transgenic mice, for use in any antibody discovery program and against any therapeutic target.

Read more  here.